Adverse pregnancy outcomes associated with moderate elevations in blood pressure or blood glucose in Ugandan women; a prospective cohort study. by Milln, Jack et al.
Original Research ajog.orgAdverse pregnancy outcomes associated with
moderate elevations in blood pressure or blood
glucose in Ugandan women; a prospective cohort
study
Jack Milln, MBBS; Betty Nakabuye, MMeD; Barnabas Natamba, PhD; Isaac Sekitoleko, MSc; Michael Mubiru, BSc;
Arthur Namara, MSc; Samuel Tumwesigire, MbChB; Tino Salome, MPH; Mandy Mirembe, MSc; Ayoub Kakanda, MSc;
Brian Agaba, MMeD; Faridah Nansubuga, MMeD; Daniel Zaake, MMeD; Ben Ayiko, MMeD; Herbert Kalema, MMeD;
Sarah Nakubulwa, PhD; Musa Sekikubo, PhD; Annettee Nakimuli, PhD; Emily L. Webb, PhD; Moffat J. Nyirenda, PhDBACKGROUND: The association between overt hypertension and diabetes and adverse pregnancy outcomes is well documented. Recent
evidence suggests that even moderate elevations in blood pressure or blood glucose may confer a significant risk in a dose-dependent manner.
However, these studies have primarily been undertaken in white populations in high-income settings. Hypertension and diabetes are emerging as
major public health issues in sub-Saharan Africa as the region undergoes rapid urbanization. It is therefore important to understand how such
noncommunicable conditions contribute to pregnancy outcomes in these populations.
OBJECTIVE: This study aimed to determine the association between stage 1 hypertension or fasting blood glucose in the gestational diabetes
mellitus-range and adverse pregnancy outcomes in Uganda, and to describe the effects of other contributing factors such as maternal obesity.
STUDY DESIGN: This was a prospective cohort study of 2857 women at 5 major hospitals in urban and semiurban central Uganda. Women
were enrolled at 24 to 28 weeks’ gestation. Data about the maternal demographics, anthropometrics, fasting venous blood glucose, blood pressure,
and pregnancy outcomes were collected. Moderate elevations in blood pressure and blood glucose were defined using the latest American College
of Cardiology and American Heart Association definition of stage 1 hypertension and the World Health Organization’s criteria for fasting blood glucose
in the gestational diabetes mellitus-range. The primary outcomes of interest were perinatal death and large birthweight for gestational age, and the
secondary outcomes were preterm birth, cesarean delivery, and neonatal admission. A multivariable logistic regression analysis was used.
RESULTS: Stage 1 hypertension increased the odds of perinatal death by more than 2-fold (adjusted odds ratio, 2.68; 95% confidence inter-
val, 1.36−5.29), with a positive but insignificant association with preterm birth. Hyperglycemia in the gestational diabetes mellitus-range was
associated with cesarean delivery only (adjusted odds ratio, 1.65; 95% confidence interval, 1.20−2.27). Maternal obesity increased the risk of
having large birthweight babies (adjusted odds ratio, 2.30; 95% confidence interval, 1.74−3.02), a cesarean delivery (adjusted odds ratio, 2.75;
95% confidence interval, 2.17−3.48), and neonatal admission (adjusted odds ratio, 1.63; 95% confidence interval, 1.16−2.30).
CONCLUSION: Moderate elevations in blood pressure and maternal obesity are stronger predictors of adverse maternal and neonatal out-
comes than moderate elevations in blood glucose levels and should be the focus of intervention in these resource-poor settings. Further research
is needed to determine the cost-effectiveness of identifying and managing moderate elevations in blood pressure and maternal obesity.
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Why was this study conducted?
Hypertension and diabetes are emerging public health issues in sub-Saharan
Africa. This study aimed to determine the association between stage 1 hyperten-
sion or mild fasting hyperglycemia and adverse pregnancy outcomes in Africa.
Key findings
Stage 1 hypertension increased the odds of perinatal death by almost 3-fold.
Although fasting blood glucose levels in the gestational diabetes mellitus-range
was associated with a positive trend for large birthweight babies, this was clearly
exceeded by the contribution of maternal obesity.
What does this add to what is known?
Moderate elevations in blood pressure and maternal obesity are stronger predic-
tors of adverse maternal and neonatal outcomes than moderate elevations in
blood glucose levels. These should be the focus of intervention and management
in the resource-limited setting.
Original Research ajog.orgIntroduction
Hypertensive and hyperglycemic disor-
ders of pregnancy are 2 of the most
common pregnancy complications
associated with both short- and long-
term adverse maternal and neonatal
outcomes. The association between
poor outcomes and severe forms of
these disorders, such as chronic hyper-
tension and diabetes in pregnancy
(DIP), is clear.1,2 However, the contri-
bution of less-severe elevations in blood
pressure or milder levels of hyperglyce-
mia in the gestational diabetes mellitus
(GDM) range remains debatable.
Recent evidence suggests that there
may be a graded risk across the spec-
trum of hypertension or hyperglycemia.
For example, there is now widespread
recognition of a continuous association
between blood pressure and cardiovas-
cular risk. This has led to further cate-
gorization into normal, elevated
(systolic blood pressure [SBP], 120
−129 mm Hg; diastolic blood pressure
[DBP], <80 mm Hg), stage 1 (SBP, 130
−139 mm Hg; DBP, 80−89 mm Hg),
and stage 2 (SBP ≥140 mm Hg; DBP
≥90 mm Hg) hypertension by the
American College of Cardiology and
the American Heart Association (ACA/
AHA).3 Although publications by the
World Health Organization (WHO)
(2017),4 American College of Obstetri-
cians and Gynecologists (2019),5 and
National Institute for Health and2 AJOG Global Reports May 2021Clinical Excellence (2019)6 still recog-
nize a cutoff of ≥140/90 mm Hg in
pregnancy, they acknowledge an accu-
mulating body of evidence suggesting a
graded association between more mod-
erate elevations in blood pressure and
adverse pregnancy outcomes.7−14 Simi-
larly, the Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) study
showed hyperglycemia within the
GDM-range was linearly associated
with adverse pregnancy outcomes, nota-
bly large birthweight (>90th centile).15
This has led to the recent tightening of
international diagnostic criteria for
GDM to capture women with milder
derangements in glucose control16 and
implementation of interventions to
manage even mild GDM.17−19
Most studies on the association
between hyperglycemia or blood pres-
sure and pregnancy outcomes have
been undertaken in high-income coun-
tries. The benefits of these screening
and management approaches may not
necessarily be directly translatable to
other populations, particularly those in
resource-poor settings, such as sub-
Saharan Africa. Diabetes and hyperten-
sion are emerging as major public
health problems in the region driven by
changing demographics, socioeco-
nomic, and lifestyle patterns, and it is
likely that the burden of these disorders
during pregnancy will mirror the rise in
the general population. Indeed, theInternational Diabetes Federation esti-
mates that 1 in 6 women in the African
region may be affected by hyperglyce-
mia in pregnancy,20 and hypertensive
disorders in pregnancy are one of the
most common causes of maternal
death.21 Although blood pressure and
blood glucose measurements are
accepted parts of routine surveillance
during antenatal care, active interven-
tion is currently usually restricted to
severe forms of hypertensive or hyper-
glycemic disorders. There have been
only a few rigorous studies on the rela-
tionships between hypertension or dia-
betes, particularly in their milder forms,
and pregnancy outcomes in sub-
Saharan Africa.22−24
This study aimed to critically assess
the relationship between stage 1 hyper-
tension or fasting blood glucose levels
in the GDM-range and adverse preg-
nancy outcomes, notably perinatal
death and large birthweight, in women
living in urban and peri-urban Uganda.
We also examined the influence of other
variables such as body mass index




This observational cohort study was
nested within a larger study to under-
stand the burden and determinants of
hyperglycemia in pregnancy in Uganda.
We recruited women attending antena-
tal care at 5 major hospitals in urban
and peri-urban areas of central Uganda
between June 13, 2018, and October 31,
2019. Three of these hospitals are public
facilities managed by the Uganda Min-
istry of Health, and 2 are private, not-
for-profit hospitals managed by the
Uganda Catholic Medical Services
Bureau. Uganda is a low-income coun-
try in East Africa with an annual Gross
Domestic Product of $643 per capita
($1.76 per day).25 Although great prog-
ress has been made in recent decades,
the maternal mortality ratio (MMR)
remains high at 368 per 100,000 live
births, as does the perinatal mortality
rate (PNMR) at 42 per 1000 births.26,27
These figures are even higher at our
study sites (MMR, 401/100,000; PNMR,
ajog.org Original Research67/1000; 2019 figures collated from all
study sites, unpublished), presumably
because of the high-risk nature of the
cases referred from other centers. Simi-
larly, although countrywide cesarean
delivery rates are relatively low (11% in
urban areas and 5% in rural areas),27
the rate in equivalent regional referral
hospitals can be above 30%.28
Participants
Pregnant women were eligible to partic-
ipate if they were 18 years or older (age
of consent) and between 24 and 28
weeks of gestation based on the date of
last menstrual period or the earliest
obstetrical ultrasound scan when avail-
able. Women were excluded if they met
1 or more of the following exclusion cri-
teria: less than 18 years of age, multiple
pregnancy, significant medical comor-
bidity (such as heart failure, renal dis-
ease, severe anemia), a known diagnosis
of diabetes, inability to provide
informed consent, or plans to deliver at
a nonstudy facility. Women were
approached in the antenatal clinic by
the research team and screened for the
inclusion and exclusion criteria.
Women with stage 2 hypertension
(≥140/90 mm Hg) or overt hyperglyce-
mia in the DIP-range (fasting blood glu-
cose level of ≥7.0 mmol/L based on the
International Association of the Diabetes
and Pregnancy Study Groups (IADPSG)
and WHO criteria29) were referred for
management by the local obstetrical
team, and were excluded from subse-
quent analyses. Women with stage 1
hypertension (SBP, 130−139 mm Hg;
DBP, 80−89 mm Hg) or hyperglycemia
in the GDM-range (fasting venous blood
glucose level of 5.1−6.9 mmol/L based
on the IADPSG and WHO criteria29)
were given advice and managed by the
local clinical team and were included in
the analyses.
At recruitment, standardized ques-
tionnaires were used to collect data about
the socio-demographic background,
medical (including HIV status), and
reproductive history (parity, gravidity,
and complications in previous pregnan-
cies). Weight and height were measured
by trained study field workers usingcalibrated Seca scales and stadiometers.
After 30 minutes of rest, 3 seated blood
pressure measurements, with 5 minutes
rest between readings, were collected on
the right arm using portable sphygmom-
anometers (OMRON-Healthcare-Co
HEM-7211-E-Model-M6, Kyoto, Japan).
Women were asked to fast overnight for
at least 8 hours before a fasting venous
blood glucose level was determined.
Samples were analyzed centrally at the
Medical Research Council/Uganda Virus
Research Institute and London School of
Hygiene and Tropical Medicine Clinical
and Diagnostics Laboratory in Entebbe,
Uganda, within 4 hours of collection, or
stored at80°C for subsequent analysis.
Collection of outcome data
Maternal and neonatal outcomes were
extracted from the mothers’ records at
the time of delivery and recorded by
midwives. These included maternal
antenatal complications (hypertensive
disorders of pregnancy, poly- or oligo-
hydramnios), delivery complications
(prolonged labor and ruptured uterus),
mode of delivery, birthweight, and ges-
tational age of the neonate. Hyperten-
sive disorders of pregnancy included
gestational hypertension, preeclampsia,
and eclampsia. Large for gestational age
was defined as a birthweight of >90th
centile using the Intergrowth-21 popu-
lation standards.30 Macrosomia and a
low birthweight were defined as birth-
weights of >4 kg and <2.5 kg, respec-
tively. Further data were recorded at the
time of discharge from hospital and
included neonatal complications (neo-
natal admission, hypoglycemia, jaun-
dice) and neonatal death. Neonatal
admission was defined as formal admis-
sion of the neonate to the special baby
unit for observation or treatment
beyond routine neonatal care.
Definition of primary and secondary
outcomes
The primary outcomes were perinatal
death (stillbirth >24 weeks and neonatal
death <28 days) and large birthweight
for gestational age. Secondary outcomes
were preterm birth (<37 weeks), cesar-
ean delivery, and neonatal admission.Statistical analysis
The participants’ baseline characteris-
tics were summarized using means,
medians, standard deviations, and inter-
quartile ranges for continuous variables
where applicable. The categorical data
were summarized using numbers and
proportions. The sample size was calcu-
lated for the wider study and deter-
mined by an estimation of the
prevalence of hyperglycemia in preg-
nancy in the population. The sample
size was, therefore, not calculated on the
basis of these perinatal outcomes. A mul-
tivariable logistic regression analysis was
used to investigate the effect of stage 1
hypertension (SBP, 130−139 mm Hg;
DBP, 80−89 mm Hg based on ACA/
AHA criteria3) and hyperglycemia in the
GDM-range (fasting venous blood glu-
cose level, 5.1−6.9 mmol/L based on the
IADPSG and WHO criteria29) on each
of the primary and secondary outcomes.
Confounding variables were identified by
univariate analysis or widespread accep-
tance of their potential confounding
effect. These included midgestational
BMI, maternal height, maternal age, par-
ity, HIV status, previous macrosomia,
and study site. An additional exploratory
analysis was undertaken to explore if our
variables of interest operated in a syner-
gistic manner with another common risk
factor, obesity. Adjustments were made
for the same confounding variables as
the primary analysis. Results from the
final adjusted models are presented as
odds ratios (OR) and their 95% confi-
dence intervals (CIs). All analyses were
conducted in Stata 15.1 (College Station,
TX).Ethical approval
This research project was approved by
the research and ethics committee of
the Uganda Virus Research Institute
(approval GC/127/19/04/625) and the
Uganda National Council for Science
and Technology (approval HS2340). All
participating women gave informed
consent, indicated either with a signa-
ture or thumbprint. A minimal com-
pensation was provided for the
participants’ time and travel.May 2021 AJOG Global Reports 3
FIGURE
Flow chart of participant enrollment throughout the study
Assessed for eligibility 
(n=4,796)
Not enrolled (n=944)
Age <18 years 
Non singleton pregnancy 
Significant medical condition 





Included in analysis (n=2,857)
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TABLE 1
Characteristics of study participants




Age (y), mean§SD 26.9§5.5
Midgestation BMI, mean§SD 27.7§6.72
Overweight (25−30 kg/m2), (n/N) % (1087/2854) 38.1
Obese >30 kg/m2, (n/N) % (801/2854) 28.1
Maternal height (cm), mean§SD 158.7§6.11
Stage 1 hypertension, (n/N) % (200/2857) 7.00
SBP 130−139 mm Hg
DBP 80−89 mm Hg
Hyperglycemia in GDM-range, (n/N) % (187/2857) 6.55
Fasting glucose 5.1−6.9 mmol/L
Previous macrosomia, (n/N) % (236/2716) 8.69
Parity, (n/N) %
Nulliparous (905/2857) 31.4
HIV status, (n/N) %
Positive (89/2857) 3.1
BMI, body mass index; DBP, diastolic blood pressure; GDM, gestational diabetes mellitus; SBP, systolic blood pressure; SD,
standard deviation.
Milln. Moderate elevations in blood pressure or glucose and adverse pregnancy outcomes in Uganda. Am J Obstet
Gynecol Glob Rep 2021.
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Participants
This study enrolled 3852 participants. Of
these, 2857 participants were included in
the analysis. A total of 66 participants
were excluded from analysis because of
confirmed stage 2 hypertension (≥140/
90 mm Hg) or overt hyperglycemia in
the DIP-range (fasting blood glucose
level of ≥7.0 mmol/L). The remainder of
the participants (n=929) were excluded
because they had incomplete laboratory
and/or outcome data (Figure). Those
excluded with incomplete data had simi-
lar baseline characteristics as those
included in the final analysis.
Maternal characteristics
The characteristics of the participants are
displayed in Table 1. All women in the
study were of black ethnicity. The mean
age of the participants was 26.9 years.
There were 200 women with stage 1
hypertension (SBP, 130−139 mm Hg;
DBP, 80−89 mm Hg) and 187 women
with hyperglycemia in the GDM-range
(fasting venous blood glucose level of 5.1
−6.9 mmol/L); of these, 23 women had
both. The mean maternal BMI was 27.7
kg/m2; 1087 (38.1%) women were over-
weight and 802 (28.1%) were obese.
Nearly one-third of women were primi-
gravid (905; 31.4%), 768 (26.9%) had
1 child, and 1184 (41.5%) had more than
1 child.4 AJOG Global Reports May 2021Maternal and neonatal outcomes
The maternal and neonatal outcomes
are displayed in Table 2. One maternaldeath was recorded. A total of 3.7% of
the participants subsequently developed
hypertensive disorders of pregnancies,
whereas 1.4% either had polyhydram-
nios or oligohydramnios. Almost one-
third of the deliveries were by cesarean
delivery, of which approximately three-
quarters (73.2%) were recorded as
“Emergency” procedures and 26.8%
recorded as “Elective.”
There were 74 perinatal deaths, equat-
ing to a perinatal mortality rate of 26 per
1000 births. The mean birthweight of the
neonates was 3275.8 g, of which 574
(22.2%) were large for gestational age on
the basis of the Intergrowth-21 popula-
tion standards. Preterm birth (<37
weeks) was recorded in 355 (12.6%) of
the deliveries. Of the live deliveries, 321
(11.5%) were admitted to the neonatal
unit with a median length of stay of
2 days. Neonatal hypoglycemia and jaun-
dice were recorded in 0.4% and 1.7% of
the cases, respectively.
TABLE 2
Maternal and neonatal delivery outcomes of participants
Category (Proportion) %
Maternal outcomes
Maternal death (1/2857) 0.03
Antepartum complications
Hypertensive disorder (105/2857) 3.7
Poly- or oligohydramnios (41/2857) 1.4
Cesarean delivery (827/2814) 29.4
Maternal delivery complications
Prolonged labor (182/2857) 6.4
Ruptured uterus (5/2857) 0.2
Neonatal outcomes
Perinatal mortality (74/2857) 2.6
Stillbirth (>24 wk) (43/2857) 1.5
Neonatal death (<28 d) (31/2814) 1.1
Mean birthweight (g), mean§SD 3275.8§546
LGA (>90th centile) (574/2706) 22.2
Macrosomia (>4 kg) (236/2716) 8.7
SGA (<10th centile) (252/2706) 9.3
Low birthweight (<2.5 kg) (226/2716) 8.3
Mean GA at delivery (wk), mean§SD 38.7§1.8
Very Preterm birth (<34 wk) (54/2830) 1.9
Preterm birth (<37 wk) (355/2830) 12.6
Neonatal admission (321/2793) 11.5




GA, gestational age; IQR, interquartile range; LGA, large for gestational age; SGA, small for gestational age; SD, standard
deviation.
Milln. Moderate elevations in blood pressure or glucose and adverse pregnancy outcomes in Uganda. Am J Obstet
Gynecol Glob Rep 2021.
ajog.org Original ResearchAssociations with primary and
secondary outcomes
Results of the multivariate analysis are
displayed in Table 3. Of the 2 variables,
stage 1 hypertension (adjusted OR
[aOR], 2.68; 95% CI, 1.36−5.29), but
not hyperglycemia in the GDM-range
(aOR, 0.74; 95% CI, 0.26−2.07), was
associated with an increased risk of
perinatal death. Neither elevations in
blood pressure nor fasting blood glucose
levels were significantly associated with
an increased risk of having large forgestational age babies. Among the sec-
ondary outcomes, elevated fasting blood
glucose levels (aOR, 1.65; 95% CI, 1.20
−2.27), but not blood pressure (aOR,
0.87; 95% CI, 0.62−1.30), was associ-
ated with an increased likelihood of
cesarean delivery. Interestingly, it was
maternal obesity (independent of
hyperglycemia and increased blood
pressure) that affected a number of the
outcomes, increasing the risk of having
large for gestational age babies (aOR,
2.30; 95% CI, 1.74−3.02), cesareandelivery (aOR, 2.75; 95% CI, 2.17−3.48),
and neonatal admission (aOR, 1.63; 95%
CI, 1.16−2.30). Other factors that were
associated with adverse pregnancy out-
comes included a self-reported history of
macrosomia, which increased the odds
of large birthweight neonates (aOR, 2.46;
95% CI, 1.84−3.27), and parity as a pre-
dictor of perinatal death (aOR, 1.30; 95%
CI, 1.06−1.59).
Combination of obesity with either
stage 1 hypertension or
hyperglycemia in the gestational
diabetes-range
Results of this exploratory analysis are
displayed in Table 4. Obesity in combi-
nation with hyperglycemia in the
GDM-range appeared to increase the
odds of having large birthweight for
gestational age neonates, cesarean deliv-
ery, and neonatal admission. Obesity in
combination with stage 1 hypertension
seemed to increase the odds of perinatal
death, but not preterm birth.
Comment
Principal findings
Our study showed an association
between stage 1 hypertension and peri-
natal death and adds to the growing
body of evidence demonstrating an
association with preterm birth. Further-
more, we demonstrated that obesity was
more closely associated with large birth-
weight neonates, cesarean delivery, and
neonatal admission than hyperglycemia
in the GDM-range. This study assessed
the effects of less-severe elevations in
hypertension and hyperglycemia on
pregnancy in Africa.
Results in the context of other
observations
In our study, the strength of the associa-
tion between stage 1 hypertension and
perinatal death was particularly strong.
We also reported a positive trend with
preterm birth, although this was not sta-
tistically significant. These findings are
in accord with the well-documented
physiological association between blood
pressure, preeclampsia, placental under-
perfusion, intrauterine growth restric-
tion, preterm delivery, and perinatal
death.31 Many previous studies reportedMay 2021 AJOG Global Reports 5
TABLE 3
Adjusted odds ratios for associations between moderately elevated bloods glucose and blood pressure, and pri-
mary and secondary outcomes with covariates
Primary outcomes Secondary outcomes
Variable Perinatal death Large for gestational age Preterm birth Cesarean delivery Neonatal admission
Stage 1 hypertension
SBP 130−139 mm Hg
DBP 80−89 mm Hg
2.68 (1.36−5.29) 0.78 (0.53−1.14) 0.87 (0.62−1.30) 1.41 (0.93−2.14) 0.93 (0.60−1.44)
Hyperglycemia GDM-range
5.1−6.9 mmol/L
0.74 (0.26−2.07) 1.34 (0.94−1.90) 1.02 (0.65−1.62) 1.65 (1.20−2.27) 1.30 (0.85−1.97)
BMI 25−30 kg/m2a 0.91 (0.52−1.60) 2.01 (1.57−2.55) 0.97 (0.75−1.26) 1.74 (1.40−2.15) 1.41 (1.03−1.94)
BMI >30 kg/m2a 0.94 (0.50−1.79) 2.30 (1.74−3.02) 0.68 (0.49−0.93) 2.75 (2.17−3.48) 1.63 (1.16−2.30)
Maternal height — 1.03 (1.01−1.04) — 0.95 (0.94−0.97) —
Maternal age 0.95 (0.90−1.01) 0.98 (0.96−1.01) 1.01 (0.99−1.04) 1.08 (1.05−1.10) 1.00 (0.98−1.03)
Previous macrosomia — 2.46 (1.84−3.27) — — —
Positive HIV status 2.00 (0.70−5.70) 0.79 (0.44−1.39) — — —
Parity 1.30 (1.06−1.59) 0.99 (0.90−1.09) — 0.76 (0.70−0.82) —
Study site (private vs public) — 1.04 (0.85−1.28) — — 2.96 (2.25−3.88)
a Compared with normal BMI range (18−25 kg/m2).
BMI, body mass index; DBP, diastolic blood pressure; GDM, gestational diabetes mellitus; SBP, systolic blood pressure.
Milln. Moderate elevations in blood pressure or glucose and adverse pregnancy outcomes in Uganda. Am J Obstet Gynecol Glob Rep 2021.
TABLE 4
Adjusted odds ratios for associations between obesity, in combination with either moderate elevations hyper-
glycemia or hypertension, and the primary and secondary outcomes
Primary outcomes Secondary outcomes
Variable Perinatal death
Large for
gestational age Preterm birth Cesarean delivery Neonatal admission
Stage 1 hypertension
plus obesity n=102
3.23 (1.41−7.41) 1.29 (0.79−2.08) 0.68 (0.34−1.37) 0.87 (0.62−1.30) 1.09 (0.62−1.92)
Hyperglycemia GDM-range
plus obesity n=92
0.34 (0.05−2.54) 1.64 (1.02−2.62) 1.10 (0.60−2.01) 2.56 (1.65−3.98) 1.92 (1.14−3.21)
GDM, gestational diabetes mellitus.
Milln. Moderate elevations in blood pressure or glucose and adverse pregnancy outcomes in Uganda. Am J Obstet Gynecol Glob Rep 2021.
Original Research ajog.organ interaction between stage 1 hyper-
tension and the development of pre-
eclampsia.7−11,32 These were performed
in high-income settings and at various
stages of gestation. In our study, we did
not consider hypertensive disorders as a
primary or secondary outcome because
of the difficulties in the standardization
of the diagnosis across the sites. We
instead focused on more easily defined
outcomes, namely perinatal death and
preterm birth, which are sufficiently
prevalent in our setting to warrant anal-
ysis. Other studies have demonstrated6 AJOG Global Reports May 2021associations between stage 1 hyperten-
sion and preterm birth.7−9,11,32 Many of
these include “indicated preterm birth,”
which we presume includes induction
of labor or cesarean delivery owing to
preeclampsia. These interventions may
be less readily available in our own set-
ting, which may in turn contribute to the
high perinatal mortality rates in line with
previous reports.21,33 Our finding that
three-quarters of cesarean deliveries were
coded as “Emergency” supports this
hypothesis. Only 1 other study has
reported on perinatal mortality,demonstrating a positive trend, although
this was not statistically significant.11
There was a trend of a positive associ-
ation between moderate elevations in
fasting blood glucose levels and large
birthweight neonates. However, this did
not reach the threshold for statistical
significance. Indeed, elevations in fast-
ing blood glucose levels were also asso-
ciated with increased rates of cesarean
delivery, presumably because of the
“large babies,” although we did not have
data on the indication for cesarean
delivery.34,35 The association between
ajog.org Original Researchfasting blood glucose levels in the
GDM-range and large birthweight is in
accord with the large, multinational
HAPO study, which described a clear
linear association between glycaemia
and the risk for large birthweight neo-
nates.16 Similarly, consistent with the
HAPO study, we found a strong rela-
tionship between obesity and large
birthweight neonates, independent of
the level of glycaemia.36 In the HAPO
study, 78% of large birthweight infants
were born to mothers with normal glu-
cose tolerance levels,34 whereas in our
study, nearly 90% of large birthweight
infants were from normoglycemic
mothers. Although there are only a few
studies that have explored the associa-
tions between hyperglycemia and birth-
weight in Africa,24 those that do exist
also point toward BMI as a more reli-
able predictor of large for gestational
age neonates than glycaemia.22,37,38
Although our study cohort was not
large enough to rigorously examine the
impact of multiple risk factors on the
pregnancy outcomes, our exploratory
analysis suggests that coexistence of our
main variables of interest with other
common risk factors (such as obesity)
may confer additional risks. This will
need confirmation in future studies.
Clinical and research implications
This study adds to an emerging body of
evidence that suggest that moderate eleva-
tions in blood pressure, below the referral
threshold recommended by the WHO
(blood pressure of >140/90 mmHg), con-
fer a significant risk for adverse perinatal
outcomes. Further research is needed to
understand if early identification and
management of this group would be effec-
tive in reducing poor pregnancy out-
comes. Furthermore, it is unclear whether
such interventions would be cost-effective
in areas where resources are limited, and
management of overt hypertension is
already lacking. One study reported that
the use of aspirin can reduce the risk of
preeclampsia in women with stage 1
hypertension, but this involved a second-
ary analysis of data from a study per-
formed almost 3 decades ago in a very
different setting.9 The clear association
with perinatal death in the absence of asignificant association with preterm birth
also warrants further investigation.
Indeed, a multicenter trial is already
underway to assess whether planned pre-
term delivery (34−37 weeks’ gestation),
compared with expectant management,
can reduce adverse pregnancy outcomes
in mothers with preeclampsia.39 These
types of studies will help to inform wider
strategies to reduce the unacceptably high
rates of stillbirths and neonatal death in
this setting, an area finally attracting
much needed attention.40
Our finding that obesity is a stronger
predictor of large birthweight neonates
and cesarean delivery than moderate
elevations in hyperglycemia, under-
scores the contribution of other (non-
glucose) physiological determinants of
fetal growth. The finding that mothers’
self-report of previous macrosomia also
predicted large birthweight neonates, as
in other settings,41,42 suggests a cluster-
ing of risk. The identification of param-
eters such as obesity and a history of
macrosomia provides the potential for
cost-effective screening and/or inter-
vention opportunities, particularly in
settings were resources are limited and
the measurement of blood glucose levels
is not currently feasible.
Strengths and limitations
To our knowledge, this is the largest pro-
spective study to critically investigate the
associations between moderate elevations
in blood pressure or blood glucose and
pregnancy outcomes in Africa. We used
standardized international definitions
(stage 1 hypertension,3 and fasting
hyperglycemia in the GDM-range29,43)
to aid in our comparison with wider lit-
erature. We made efforts to ensure that it
was as representative as possible by
recruiting from both public and private
facilities. We made use of a rigid study
protocol to collect detailed data, utilized
a high-quality central laboratory for sam-
ple analyses, and employed up-to-date
diagnostic criteria.
In our study, women with moderate
elevations in fasting blood glucose levels
and who were therefore diagnosed with
GDM, were managed by their clinicians
rather than through a study protocol;
the intensity of treatment was thereforelikely to be variable and not under study
control, which may have influenced the
outcomes. However, women with mod-
erate elevations in blood pressure were
not referred for further management, as
per national guidance. For some out-
comes (such as preeclampsia and poly-
and oligohydramnios), we relied on
healthcare records rather than active
investigation by the study team. We did
not have data regarding previous opera-
tive deliveries and could therefore not
determine whether it was a primary
cesarean delivery or not, as in the HAPO
study.15 Although serial blood pressure
recordings were taken throughout the
antenatal period, we concluded that the
heterogeneity of conditions and devices
used was not conducive of reliable results.
The loss to follow-up owing to women
delivering elsewhere may have intro-
duced bias in the outcomes reported,
although the baseline characteristics of
those included and excluded in the analy-
sis were similar. The study was per-
formed in urban and peri-urban central
Uganda, where women regularly attend
antenatal clinics. This may reduce the
generalizability to rural populations or
tertiary referral hospitals with more
selected specialist cases. This is
highlighted by the relatively low MMR
and perinatal mortality rate in our study
than the overall referral hospital figures
and those of other regions in the country.Conclusion
Our study in Uganda indicates that sub-
tle elevations in blood pressure, and to a
lesser extent blood glucose levels, during
pregnancy increase the risk for adverse
outcomes in the mother and offspring.
These data also highlight the impor-
tance of obesity as an independent
driver of these risks. Simple and cost-
effective interventions to screen and
manage these risk factors, particularly
obesity and blood pressure, might lead
to significant reductions in adverse out-
comes in this population. &
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